[1] KDIGO AKI Workgroup. Kidney disease:improving global outcomes (KDIGO) clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2012, 2:1-141.
[2] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International of the Club of Ascites. J Hepatol, 2015, 62: 968-874.
[3] Amathieu R, AI-Khafaji A, Sileanu FE, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology, 2017, 66: 1592-1600.
[4] Chawla LS, Bellomo R, Bihorac A, et al. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol, 2017, 13: 241-257.
[5] Kellum JA, Sileanu FE, Bihorac A, et al. Recovery after Acute Kidney Injury. Am J Respir Crit Care Med, 2017, 195:784-791.
[6] James MT, Levey AS, Tonelli M, et al. Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System. JAMA Netw Open, 2019, 2: e191795.
[7] Chu R, Li C, Wang S, et al. Assessment of KDIGO definitions in patients with histopathologic evidence of acute renal disease. Clin J Am Soc Nephrol, 2014, 9: 1175-1182.
[8] Uhel F, Peters-Sengers H, Falahi F, et al. MARS consortium. Mortality and host response aberrations associated with transient and persistent acute kidney injury in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med, 2020, 46:1576-1589.
[9] Inker LA, Levey AS, Pandya K, et al. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis, 2014, 64:74-85.
[10] Huelin P, Solà E, Elia C, et al. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70:319-333.
[11] Allegretti AS, Solà E, Ginès P. Clinical Application of Kidney Biomarkers in Cirrhosis. Am J Kidney Dis, 2020, 76:710-719.
[12] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019, 71: 811-822.
[13] Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol, 2021, 74: 578-583.
[14] Kashani K, Rosner MH, Haase M, et al. Quality Improvement Goals for Acute Kidney Injury. Clin J Am Soc Nephrol, 2019, 14: 941-953.
[15] Kaushal GP, Shah SV. Challenges and advances in the treatment of AKI. J Am Soc Nephrol, 2014, 25: 877-883.
[16] Lewington AJ, Cerdá J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int, 2013, 84: 457-67.
[17] Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA, 2015, 313: 837-846. |
